Leerink stays Outperform on Eli Lilly (LLY) after Jaypirca Ph3 results
Tweet Send to a Friend
Leerink Partners analyst David Risinger reiterated an Outperform rating and $1,296.00 price target on Eli Lilly (NYSE: LLY)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
